Zeus Celebrates Grand Opening of New Arden Hills, Minnesota Facility

Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a | Psychedelic Invest

NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment

June 20, 2024

API processes in the pharmaceutical industry

In this interview, News Med talks to Dr. James Mencel’s Guidance about Scaling Up API Processes.

May 23, 2024

Research highlights the need for continued surveillance of emerging SARS-CoV-2 variants and vaccines

Researchers at the Francis Crick Institute and the National Institute for Health and Care Research Biomedical Research Centre at UCLH have highlighted the importance of

March 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.